Type Private Key people Daniel M. Bradbury Net income US$-186M (FY 2009) Founded 1987 Parent organization AstraZeneca | Industry Biotechnology Operating income Revenue 758 million USD (2009) Number of employees 1,900 | |
 | ||
Products Symlin (pramlintide)
Byetta (exenatide) Headquarters San Diego, California, United States Motto Challenging Science, Changing Lives. Subsidiaries Amylin Ohio LLC, Amylin Europe ltd, Amylin Investments LLC, Amylin Puerto Rico LLC | ||
Amylin pharmaceuticals increases speed to insight with 100 million rows
Amylin Pharmaceuticals was a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.
Contents
- Amylin pharmaceuticals increases speed to insight with 100 million rows
- Amylin pharmaceuticals inc amln
- References
In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.
In December 2013, Amylin was acquired by AstraZeneca.